JP2018531892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531892A5 JP2018531892A5 JP2018507527A JP2018507527A JP2018531892A5 JP 2018531892 A5 JP2018531892 A5 JP 2018531892A5 JP 2018507527 A JP2018507527 A JP 2018507527A JP 2018507527 A JP2018507527 A JP 2018507527A JP 2018531892 A5 JP2018531892 A5 JP 2018531892A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pde3a
- subject
- cell
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021114249A JP2021169488A (ja) | 2015-08-13 | 2021-07-09 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204875P | 2015-08-13 | 2015-08-13 | |
| US62/204,875 | 2015-08-13 | ||
| PCT/US2016/046912 WO2017027854A1 (en) | 2015-08-13 | 2016-08-12 | Compositions and methods for cancer expressing pde3a or slfn12 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114249A Division JP2021169488A (ja) | 2015-08-13 | 2021-07-09 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531892A JP2018531892A (ja) | 2018-11-01 |
| JP2018531892A5 true JP2018531892A5 (enExample) | 2019-09-26 |
| JP6968054B2 JP6968054B2 (ja) | 2021-11-17 |
Family
ID=57983814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507527A Active JP6968054B2 (ja) | 2015-08-13 | 2016-08-12 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
| JP2021114249A Pending JP2021169488A (ja) | 2015-08-13 | 2021-07-09 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114249A Pending JP2021169488A (ja) | 2015-08-13 | 2021-07-09 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11207320B2 (enExample) |
| EP (1) | EP3334404B1 (enExample) |
| JP (2) | JP6968054B2 (enExample) |
| CN (2) | CN114699528A (enExample) |
| CA (1) | CA2995375C (enExample) |
| WO (1) | WO2017027854A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3411037B1 (en) | 2016-02-05 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Compounds, compositions and methods for cancer patient stratification and cancer treatment |
| CN107312824A (zh) * | 2016-04-26 | 2017-11-03 | 中国科学院上海药物研究所 | Pde3a在判断阿那格雷治疗肿瘤效果中的应用 |
| EP3661917B1 (en) | 2017-08-04 | 2022-05-11 | Bayer Aktiengesellschaft | 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| US12325880B2 (en) | 2018-11-01 | 2025-06-10 | The Broad Institute, Inc. | Identification of PDE3 modulator responsive cancers |
| CA3128293A1 (en) | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases |
| CN112402613A (zh) * | 2019-08-23 | 2021-02-26 | 中国科学院上海药物研究所 | Pde3抑制剂与细胞因子联合治疗肿瘤的应用 |
| CN117279644A (zh) * | 2021-03-03 | 2023-12-22 | 拜耳股份有限公司 | 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮 |
| CN117062819A (zh) * | 2021-03-23 | 2023-11-14 | 北京生命科学研究所 | 多环化合物及其用途 |
| CN114814221A (zh) * | 2022-02-24 | 2022-07-29 | 中南大学湘雅医院 | 一种甲状腺癌早期诊断标志物及其应用 |
| CN116705196B (zh) * | 2023-06-28 | 2025-08-19 | 湖南师范大学 | 基于符号图神经网络的药物靶标互作用预测方法及装置 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4052395A (en) | 1975-09-11 | 1977-10-04 | Sankyo Company Limited | Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones |
| US4092311A (en) | 1976-06-03 | 1978-05-30 | American Cyanamid Company | Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates |
| JPS6061570A (ja) | 1983-09-16 | 1985-04-09 | Sankyo Co Ltd | ピリダジノン誘導体及び農業用殺菌剤 |
| US5053338A (en) | 1989-09-01 | 1991-10-01 | Glaxo Inc. | Kinetic resolution of pyridazinones using lipase |
| GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| JPH05140116A (ja) | 1991-11-21 | 1993-06-08 | Nippon Soda Co Ltd | 光学活性な化合物 |
| US5856480A (en) | 1994-11-11 | 1999-01-05 | Nippon Soda Co., Ltd. | Optically active compound |
| EP1406621A2 (en) * | 2001-06-26 | 2004-04-14 | Beth Israel Deaconess Medical Center | Compositions and methods for inhibiting platelet activation and thrombosis |
| CN101538245B (zh) | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和制备药物的用途 |
| CA2782620A1 (en) * | 2009-12-01 | 2011-06-09 | Compendia Bioscience, Inc. | Classification of cancers |
| EP2739751A1 (en) | 2011-08-03 | 2014-06-11 | Signal Pharmaceuticals, LLC | Identification of gene expression profile as a predictive biomarker for lkb1 status |
| US9890127B2 (en) * | 2013-03-11 | 2018-02-13 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
| CA2927708C (en) * | 2013-10-17 | 2021-05-25 | Sartar Therapeutics Ltd | Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient |
| JP5852759B1 (ja) * | 2015-04-01 | 2016-02-03 | 株式会社キュービクス | 遺伝子発現解析による膵臓癌の検出 |
| EP3411037B1 (en) * | 2016-02-05 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Compounds, compositions and methods for cancer patient stratification and cancer treatment |
| WO2018141835A1 (en) * | 2017-02-03 | 2018-08-09 | The Broad Institute, Inc. | Compounds, compositions and methods for cancer treatment |
| US12325880B2 (en) * | 2018-11-01 | 2025-06-10 | The Broad Institute, Inc. | Identification of PDE3 modulator responsive cancers |
-
2016
- 2016-08-12 US US15/752,130 patent/US11207320B2/en active Active
- 2016-08-12 CA CA2995375A patent/CA2995375C/en active Active
- 2016-08-12 WO PCT/US2016/046912 patent/WO2017027854A1/en not_active Ceased
- 2016-08-12 CN CN202210036941.5A patent/CN114699528A/zh active Pending
- 2016-08-12 CN CN201680059256.7A patent/CN108366947B/zh active Active
- 2016-08-12 JP JP2018507527A patent/JP6968054B2/ja active Active
- 2016-08-12 EP EP16836014.7A patent/EP3334404B1/en active Active
-
2021
- 2021-07-09 JP JP2021114249A patent/JP2021169488A/ja active Pending
- 2021-11-18 US US17/530,402 patent/US20220071995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531892A5 (enExample) | ||
| Nault et al. | Biomarkers for hepatobiliary cancers | |
| Schütte et al. | Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma | |
| Herzig et al. | Molecular markers for colon diagnosis, prognosis and targeted therapy | |
| Gobin et al. | Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models | |
| Kim et al. | Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin | |
| Liu et al. | ER stress‐related ATF 6 upregulates CIP 2A and contributes to poor prognosis of colon cancer | |
| Trigka et al. | A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features | |
| Ingels et al. | Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts | |
| Duan et al. | Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine | |
| Xin et al. | miR‐20b inhibits T cell proliferation and activation via NFAT signaling pathway in thymoma‐associated myasthenia gravis | |
| MX2013004305A (es) | Metodos para determinar isotipos de anticuerpos anti-farmacos. | |
| CA2835179A1 (en) | Markers for cancer prognosis and therapy and methods of use | |
| Stjernström et al. | Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung | |
| MX2022012384A (es) | Composiciones y metodos para cribar mutaciones en el cancer de tiroides. | |
| AU2012262961A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
| EA200900927A1 (ru) | Способы определения устойчивости рака к ингибиторам гистондеацетилазы | |
| Li et al. | Suppression of long non-coding RNA MALAT1 inhibits survival and metastasis of esophagus cancer cells by sponging miR-1-3p/CORO1C/TPM3 axis | |
| WO2007085497A8 (en) | Markers for the prediction of outcome of anthracycline treatment | |
| JP2009537798A5 (enExample) | ||
| Gao et al. | C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients | |
| Seiwert | Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing | |
| Tran et al. | Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management | |
| Van Dam et al. | Potential new biomarkers for squamous carcinoma of the uterine cervix | |
| Peraldo Neia et al. | Screening for the FIG‐ROS1 fusion in biliary tract carcinomas by nested PCR |